Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Submitted by admin on February 26, 2024 - 5:16pm
Source: 
Clinical Trials Arena
News Tags: 
FDA
Bayer
breakthrough designation
non-small cell lung cancer
BAY 2927088
Headline: 
Bayer wins FDA breakthrough therapy designation for NSCLC candidate
snippet: 

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bayer for its non-small cell lung cancer (NSCLC) candidate BAY 2927088.

Do Not Allow Advertisers to Use My Personal information